Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets
Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets
April 19, 2015 at 9:17 AM EDT
Blueprint_Medicines_AACR_4.19.pdf 185.8 KB